At the beginning of 2008 there were more than 400 clinical trials underway to understand and treat Alzheimer's disease. Alzheimer's vaccine ACC-001 was just on the second stage when there appeared side effects.
The companies responsible for Phase II trials - Wyeth and Elan Corp - had to suspend dosing when they learned that a patient developed unexplained skin lesions.
The following decision was taken after discussions with Food and Drug Administration. The suspension is due to expand also outside of the U.S.
This situation has a precedent when in 2002 the work at Alzheimer's drug, known as AN-1792, was suspended due to reports of brain inflammation.
Actually this temporary difficulty can’t shade the studies of another Alzheimer's drug - AAB-001 - believed to have potential to improve cognitive function in Alzheimer's patients. And the expected minor negative share price response may be even effective to draw attention to AAB-001.